Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 15;114(50):858-865.
doi: 10.3238/arztebl.2017.0858.

Surveillance of Antibiotic Use and Resistance in Intensive Care Units (SARI)

Affiliations

Surveillance of Antibiotic Use and Resistance in Intensive Care Units (SARI)

Cornelius Remschmidt et al. Dtsch Arztebl Int. .

Abstract

Background: The project entitled Surveillance of Antibiotic Use and Resistance in Intensive Care Units (SARI) was initiated in Germany in 2000. In this article, we describe developments in antibiotic use and resistance rates in the participating intensive care units over the years 2001-2015.

Methods: The intensive care units supplied monthly figures on patient days, antibiotic use (in defined daily doses, DDD), and resistance data for 13 pathogens. The density of antibiotic use per 1000 patient days was calculated on the basis of antibiotic use, DDD, and patient days, and the resistance density per 1000 patient days was calculated from the number of resistant pathogens.

Results: In the years 2001-2015, data on 2 920 068 patient days were collected in 77 intensive care units. The average overall antibiotic use rose by 19% over this period, with a marked increase in the density of carbapenem use (from 76 to 250 DDD per 1000 patient days, +230%) and piperacillin-tazobactam use (from 42 to 146 DDD per 1000 patient days, +247%). The proportion of Escherichia coli and Klebsiella pneumoniae isolates that were resistant to third-generation cephalosporins increased markedly initially, then remained stable over the remainder of the observation period. The proportion of methicillin-resistant Staphylococcus aureus was stable over the entire period. The rates of vancomycin resistance among Enterococcus faecium isolates and imipenem resistance among gram-negative pathogens increased from 2.3% to 13.3% and from 0.1% to 0.3%, respectively.

Conclusion: The resistance density of gram-negative multiresistant pathogens in the participating intensive care units increased markedly. The rise in imipenem-resistant pathogens arouses particular concern. The increased use of broad-spectrum/reserve antibiotics may well have contributed to this development. Efforts to use antibiotics rationally, e.g., with the support of multidisciplinary "antibiotic stewardship" teams, are therefore vitally important. As participation in SARI is voluntary, these surveillance data cannot be considered representative of Germany as a whole.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trends in antibiotic use density (defined daily doses/1000 patient days) in intensive care units (N = 77) in Germany from 2001 to 2015. DDD, defined daily dose (www. whocc.no/atc_ddd_index); gen: generation
Figure 2
Figure 2
Trends in the resistance rate of vancomycin-resistant E. faecium (VRE) in SARI intensive care units (N = 77) from 2001 to 2015. Values are smoothed and show 12-month moving averages. The bold red line shows the pooled mean value of all SARI ICUs, the beige area marks the interquartile range (25th and 75th percentile), and the dotted black line the median. E. faecium: Enterococcus faecium; SARI: Surveillance der Antibiotika-Anwendung und der bakteriellen Resistenzen auf deutschen Intensivstationen [surveillance of antibiotic use and resistance in intensive care units]; ICU: intensive care unit
Figure 3
Figure 3
Trends in the incidence density of resistant pathogens in intensive care units (N = 77) from 2001 to 2015 MDRB: multidrug resistant bacteria; 3GC: 3rd generation cephalosporins; E. coli: Escherichia coli; K: pneumoniae: Klebsiella pneumoniae; A. baumannii: Acinetobacter baumannii; E. faecium: Enterococcus faecium; S. aureus: Staphylococcus aureus
eFigure
eFigure
Trends in resistance rates to third-generation cephalosporins and imipenem of selected gram-negative pathogens in SARI intensive care units (ICUs) from 2001 to 2015. a+b) resistance to third-generation cephalosporins; c–f) resistance to imipenem. Values are smoothed and reflect 12-month moving averages. The bold red line shows the pooled mean value for all SARI ICUs, the beige area marks the interquartile range (25th and 75th percentile), the dotted black line shows the median. A. baumannii: Acinetobacter baumannii; E. coli: Escherichia coli; K. pneumoniae: Klebsiella pneumoniae; P. aeruginosa: Pseudomonas aeruginosa; SARI: Surveillance der Antibiotika-Anwendung und der bakteriellen Resistenzen auf deutschen Intensivstationen [surveillance of antibiotic use and resistance in intensive care units]

Comment in

  • Changing Infection Patterns.
    Krause G. Krause G. Dtsch Arztebl Int. 2017 Dec 15;114(50):849-850. doi: 10.3238/arztebl.2017.0849. Dtsch Arztebl Int. 2017. PMID: 29271342 Free PMC article. No abstract available.

References

    1. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14:742–750. - PubMed
    1. Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387:176–187. - PubMed
    1. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13:1057–1098. - PubMed
    1. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011) Diagn Microbiol Infect Dis. 2014;78:443–448. - PubMed
    1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–2329. - PubMed

Publication types

MeSH terms

Substances